Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 1, 1997, Pages 28-32

  Fleishaker, J C ^a,b   Peters, G R ^a  

^a Global Clinical Development   (United States)

^b PFIZER INC   (United States)

Author keywords

Active metabolite; Aminosteroid; Lipid peroxidation inhibitor

Indexed keywords

21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGN 9(11) ENE 3,20 DIONE; 21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,9(11) DIENE 3,20 DIONE; AGENTS AFFECTING LIPID METABOLISM; TIRILAZAD; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PREGNATRIENES;

EID: 0031016572     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bombardt PA, Brewer JE, Johnson MG 1994 Protein binding of tirilazad (U-74006) in human, Sprague-Dawley rat, beagle dog and cynomolgus monkey serum. J Pharmacol Exp Ther 269: 145-150
2. Braughler JM, Hall ED, Jacobsen J, McCall JM, Means ED 1989 The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 14: 143-152
3. Fleishaker JC, Peters GR, Cathcart KS, Steenwyk RC 1993 Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger. II. Multiple dose administration. J Clin Pharmacol 33: 182-190
4. Fleishaker JC, Hulst LK, Peters GR 1994 Multiple dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers. Int J Clin Pharmacol Ther 32: 223-230
5. Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Peters GR 1996 Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther 277: 991-998
6. Gibaldi M, Perrier D 1985 Pharmacokinetics (2nd ed). Marcel Dekker, New York
7. Hopkins NK, Larson MK, Hanson GD 1993 Determination of tirilazad mesylate (U-74,006F) and its metabolite (M-1) in human plasma using high performance liquid chromatography. Presented at the 4th International Symposium on Pharmaceutical and Biomedical Analysis, Baltimore, MD, April, 1993
8. Kassell NF, Haley EC, Apperson-Hansen C, Alves WM and the participants 1996 A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe/Australia/New Zealand. J Neurosurg 84: 221-228
9. SAS Institute 1985 SAS User's Guide: Statistics, Version 5 Edition 1985. SAS Institute, Cary, North Carolina
10. Smith SL, Scherch HM, Hall ED 1996 Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury. J Neurosurg 84: 229-233
11. Wienkers LC, Steenwyk RC, Sanders PE, Pearson PG 1996 Biotransformation of tirilazad in human: 1. cytochrome p450 3a-mediated hydorxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther 277: 992-990